1. Academic Validation
  2. A novel inhibitor stabilizes the inactive conformation of MAPK-interacting kinase 1

A novel inhibitor stabilizes the inactive conformation of MAPK-interacting kinase 1

  • Acta Crystallogr F Struct Biol Commun. 2018 Mar 1;74(Pt 3):156-160. doi: 10.1107/S2053230X18002108.
Yumi Matsui 1 Isao Yasumatsu 1 Ken Ichi Yoshida 2 Shin Iimura 2 Yutaka Ikeno 1 Takako Nawano 1 Hajime Fukano 1 Osamu Ubukata 1 Hiroyuki Hanzawa 1 Fumie Tanzawa 2 Takeshi Isoyama 2
Affiliations

Affiliations

  • 1 Daiichi Sankyo RD Novare Co. Ltd, 1-16-13 Kita-Kasai, Edogawa-ku, Tokyo 134-8630, Japan.
  • 2 R&D Division, Daiichi Sankyo Co. Ltd, 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan.
Abstract

Mitogen-activated protein kinase (MAPK)-interacting kinases 1 (MNK1) and 2 (MNK2) modulate translation initiation through the phosphorylation of eukaryotic translation initiation factor 4E, which promotes tumorigenesis. However, MNK1 and MNK2 are dispensable in normal cells, suggesting that the inhibition of MNK1 and MNK2 could be effective in Cancer therapy. To provide a structural basis for MNK1 inhibition, a novel MNK1 Inhibitor was discovered and the crystal structure of MNK1 in complex with this inhibitor was determined. The crystal structure revealed that the inhibitor binds to the autoinhibited state of MNK1, stabilizing the Mnk-specific DFD motif in the DFD-out conformation, thus preventing MNK1 from switching to the active conformation and thereby inhibiting the kinase activity. These results provide a valuable platform for the structure-guided design of MNK1 inhibitors.

Keywords

DS12881479; MAPK-interacting kinase 1; Mnk1; inactive conformations; kinase; kinase inhibitors; transferases.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-148105
    99.10%, MNK1 Inhibitor
    MNK